文献速递角膜与眼表疾病

糖尿病供体角膜内皮移植研究:成功DMEK术后1年内皮细胞丢失的随机临床试验

Endothelial Cell Loss 1 Year After Successful DMEK in the Diabetes Endothelial Keratoplasty Study: A Randomized Clinical Trial.
PubMed 文献 · JAMA Ophthalmol · 2025-01-01

这项多中心、双盲随机临床试验纳入1274只成功行DMEK术的患眼,比较糖尿病与非糖尿病供体角膜移植后1年的内皮细胞丢失和形态学变化。结果显示两组1年内皮细胞丢失、内皮细胞密度、细胞面积变异系数和六边形细胞百分比均无显著差异,支持在角膜内皮移植中使用糖尿病供体角膜。

要点

  • 糖尿病与非糖尿病供体组1年内皮细胞丢失分别为28.0%与28.3%,校正均数差-0.4%(95%CI -2.3%至1.4%)。
  • 1年内皮细胞密度两组分别为1920与1927 cells/mm2,校正均数差10 cells/mm2(95%CI -36至56,P=0.95)。
  • 1年细胞面积变异系数与六边形细胞百分比两组均无显著差异,内皮细胞密度与糖尿病严重程度无关(P=0.97)。

核心结论

  • 本随机临床试验发现成功DMEK术后1年内皮细胞丢失和形态学变化不受供体糖尿病状态影响。
  • 结合本试验显示的糖尿病与非糖尿病供体组织1年移植成功率相当,这些发现支持在角膜内皮移植手术中使用糖尿病供体角膜。

研究设计与样本

  • 多中心、双盲、随机临床试验,2022年2月至2024年7月在美国28个临床中心(46名外科医生)和13家眼库开展。
  • 纳入成功行DMEK术(主要为Fuchs内皮性角膜营养不良)且至少有1张可分析术后内皮图像的患眼,共1274只眼(982名受者,平均年龄70岁,女性569名占57.9%)。
  • 供体角膜按最小化法分配至无糖尿病组(816只眼,64.1%)与糖尿病组(458只眼,35.9%),约2:1分布。

主要发现

  • 术前无糖尿病组与糖尿病组平均中央内皮细胞密度分别为2676与2671 cells/mm2。
  • 1年平均内皮细胞丢失无糖尿病组为28.3% vs 糖尿病组28.0%(校正均数差-0.4%,95%CI -2.3%至1.4%)。
  • 1年平均内皮细胞密度无糖尿病组1927 cells/mm2 vs 糖尿病组1920 cells/mm2(校正均数差10 cells/mm2,95%CI -36至56,P=0.95)。
  • 1年细胞面积变异系数无糖尿病组31.5% vs 糖尿病组31.4%(校正均数差-0.4%,95%CI -0.9%至0.1%,P=0.51)。
  • 1年六边形细胞百分比无糖尿病组57.7% vs 糖尿病组57.2%(校正均数差0.1%,95%CI -0.8%至0.9%,P=0.33)。

关键数值与推荐

  • 1年内皮细胞密度与供体糖尿病严重程度无关(P=0.97)。

临床怎么用

  • 作者认为,结合本试验显示的糖尿病与非糖尿病供体组织1年移植成功率相当,这些发现支持在角膜内皮移植手术中使用糖尿病供体角膜。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: The effect of cornea donor diabetes on endothelial cell density (ECD) and morphometry after Descemet membrane endothelial keratoplasty (DMEK) is not known. OBJECTIVE: To determine whether endothelial cell loss (ECL) and morphometric changes 1 year after successful DMEK are related to cornea donor's diabetes status. DESIGN, SETTING, AND PARTICIPANTS: This was a multicenter, double-masked, randomized clinical trial conducted from February 2022 to July 2024 at 28 US clinical sites (46 surgeons) and 13 eye banks. Included in the trial were the eyes of recipients (some of whom received tissue from donors without diabetes and others who received tissue from donors with diabetes) who underwent successful DMEK, primarily for Fuchs endothelial corneal dystrophy, and had at least 1 analyzable postoperative endothelial image. INTERVENTION: DMEK performed with a cornea from a donor without or with diabetes, assigned using a minimization procedure to achieve an approximate 2:1 distribution. MAIN OUTCOMES AND MEASURES: ECD, ECL, coefficient of variation in cell area (CV), and percentage of hexagonal cells (HEX) at 1 year from eye bank and postoperative specular central endothelial images. RESULTS: A total 1274 eyes of 982 recipients (mean [SD] age, 70 [8] years; 569 female [57.9%]; 816 [64.1%] with tissue from donors without diabetes and 458 [35.9%] with tissue from donors with diabetes) were included in the study. Preoperatively, mean (SD) central ECD in tissue from donors without diabetes and with diabetes were 2676 (290) cells/mm2 and 2671 (286) cells/mm2, respectively. At 1 year, mean (SD) ECL was 28.3% (16.1%) and 28.0% (17.0%), in the donor groups without and with diabetes, respectively (adjusted mean difference = -0.4%; 95% CI, -2.3% to 1.4%), resulting in a mean (SD) 1-year ECD of 1927 (498) cells/mm2 and 1920 (496) cells/mm2, respectively (adjusted mean difference = 10 cells/mm2; 95% CI, -36 to 56; P = .95). No difference in ECD at 1 year associated with diabetes severity was noted (P = .97). Mean (SD) CV did not differ at 1 year between the 2 groups of eyes (31.5% [4.1%] vs 31.4% [4.1%]; adjusted mean difference = -0.4%; 95% CI, -0.9% to 0.1%; P = .51), and mean (SD) HEX did not differ at 1 year between the 2 groups of eyes (57.7% [5.8%] vs 57.2% [5.8%]; adjusted mean difference = 0.1%, 95% CI, -0.8% to 0.9%; P = .33). CONCLUSIONS AND RELEVANCE: This randomized clinical trial found that ECL and morphometry 1 year after DMEK were not affected by cornea donor diabetes status. With comparable 1-year graft success with tissue from donors with and without diabetes demonstrated in this trial, these findings support the use of corneas from donors with diabetes for endothelial keratoplasty procedures. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT05134480.

来源:JAMA Ophthalmol,查看原文。版权归原作者所有。

引用

  1. Lass JH, Benetz BA, Verdier DD, et al. Endothelial Cell Loss 1 Year After Successful DMEK in the Diabetes Endothelial Keratoplasty Study: A Randomized Clinical Trial. JAMA Ophthalmol. 2025. PMID: 41105099. doi:10.1001/jamaophthalmol.2025.4261

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。